Nikhil Mayor
@NikhilMayor
Followers
432
Following
4K
Media
35
Statuses
540
NIHR Academic Clinical Fellow in Urology @IP_London. @bartsthelondon alumnus. 🏏 and🎾 fan.
London, England
Joined January 2018
Great to see our PhD student @NikhilMayor present the #TRANSFORM trial at tonight’s @Uroweb UROwebinar: The role of MRI in prostate cancer screening and diagnosis Recruitment to start later this year! @LondonProstate1 @ProstateUK
0
6
26
Did you know #ProstateCancer is the most common cancer in males in the UK? Join S&C's Prof Rakesh Heer for his Imperial Inaugural on 7 May, where he will discuss his academic journey challenging the science behind prostate cancer ⬇️ https://t.co/bia1rs3tmi
0
9
15
Very nice! Great job by @NikhilMayor Congratulations to CI Matt Winkler
Building on this morning’s #NeuroSAFE data, @NikhilMayor presents late-breaking results from #IP8FLUORESCE, assessing the diagnostic accuracy of FCM for detecting positive margins intra-op Feasible, quick and good sensitivity and specificity for detecting margins ≥3mm! #EAU25
0
2
11
💬 #TRANSFORM will look at new ways of screening to reduce false positives, reduce biopsy rates and reduce diagnosing low risk cancers whilst finding more high risk cancers that need to be treated. @LondonProstate1 @ProstateUK @NIHRresearch
https://t.co/iBOfx2IfxH
lbc.co.uk
The debate on screening for prostate cancer has been raging for over two decades.
0
4
13
Great to see Professor Hashim Ahmed @LondonProstate1 talking @NickFerrariLBC through his PSA blood test this morning, and sharing why the TRANSFORM trial is vital for finding the best way to screen men for #ProstateCancer. https://t.co/WZHdqKFqYa
prostatecanceruk.org
The £42 million TRANSFORM trial, the biggest prostate cancer screening trial in 20 years, could save the lives of thousands of men each year.
💬 #TRANSFORM will look at new ways of screening to reduce false positives, reduce biopsy rates and reduce diagnosing low risk cancers whilst finding more high risk cancers that need to be treated. @LondonProstate1 @ProstateUK @NIHRresearch
https://t.co/iBOfx2IfxH
0
5
13
Two weeks to go! Imperial Prostate Masterclass in association with the Focal Therapy Society.
0
5
13
Exciting to see results of @NeuroSAFEproof presented by Greg Shaw in #GameChanger session @Uroweb #EAU25 So good to have #RCTs in surgical practice - previously lacking for #nervespare as @roodvdb highlighted Synchronous publication @TheLancetOncol 👏 https://t.co/t4HVLnb3jH
0
13
30
Next @cut_tt_chase presents 5-year follow-up data for patients discharged with negative MRI/biopsy from our #RAPID pathway #EAU25 1 in 12 were subsequently diagnosed with GG2+ cancer and 1 in 20 needed treatment - this further highlights the efficacy of MRI-based diagnostics!
1
10
25
Building on this morning’s #NeuroSAFE data, @NikhilMayor presents late-breaking results from #IP8FLUORESCE, assessing the diagnostic accuracy of FCM for detecting positive margins intra-op Feasible, quick and good sensitivity and specificity for detecting margins ≥3mm! #EAU25
0
6
21
Our experience with the Histolog Scanner from 160 cases in #IP8FLUORESCE. Highly sensitive for “clinically significant” margins and truly “real-time” results 📝 Well done team 👏🏽
Building on this morning’s #NeuroSAFE data, @NikhilMayor presents late-breaking results from #IP8FLUORESCE, assessing the diagnostic accuracy of FCM for detecting positive margins intra-op Feasible, quick and good sensitivity and specificity for detecting margins ≥3mm! #EAU25
0
5
14
Excellent presentation by @lyanleung on 5-year outcomes after Rezum in >80mL prostates #EAU25 🇪🇸 75% retreatment-free at 5 years and the majority satisfied with their treatment!
1
8
28
Great job by @NikhilMayor on the TRANSFORM article in European Urology Today congress news magazine #EAU25 #EAU2025 @ProstateUKProfs
And now Prof Ahmed @LondonProstate1 presents an update on the #TRANSFORM randomised prostate cancer screening study in the plenary session - recruitment starting later this year to answer some of the biggest questions in screening 📝📈 #EAU25
0
4
17
Lastly for @IP_London today @ #EAU25 🇪🇸 is @Reddy4Urology in the new technologies & focal therapy in localised PCa session Traditional risk classification strategies developed for radical treatment are not transferrable to focal therapy outcomes. Risk models are in development!
0
7
25
Be sure to catch @cut_tt_chase presentation 26th March on 10 year outcomes of transurethral laser ablation (TULA) of superficial bladder cancer. #eau25 Pink area N101 10.45am 📣
0
2
9
Trial CI @LabBryant delighted to read out #TRANSLATE_Trial results during #GameChanger session @Uroweb #EAU25 Thank you to all our investigators, recruiting sites, funders @NIHRresearch and, most importantly, our 1126 pts! https://t.co/HgQkrBKbsb Trial visual abstract below ⬇️
3
38
74
And now Prof Ahmed @LondonProstate1 presents an update on the #TRANSFORM randomised prostate cancer screening study in the plenary session - recruitment starting later this year to answer some of the biggest questions in screening 📝📈 #EAU25
0
14
34
Nice presentation here at #EAU25 from my PhD student @Archana_GK1
#IP9-ATLAS answering the question on MRI intensified active surveillance follow up vs standard of care - recruiting well in the UK
Next is @Archana_GK1 discussing the #IP9ATLAS trial For active surveillance, is regular MRI superior to standard care for detecting progression? Recruitment is open and the trial will randomise 1263 patients in 30 centres. Watch this space! #EAU25 🇪🇸
0
4
21
Next up: PhD Fellow @AJWLight presents an update from the multicentre blinded #IP8FLUORESCE study evaluating #ConfocalMicroscopy for margin status in #RadicalProstatectomy - recruitment complete and results out on Monday 24/03 at #EAU25
0
5
23
📣 Join Clinical Lecturer Mr Martin Connor as he presents the first @IP_London randomised controlled trial - #IP2ATLANTA internal pilot results are out! Live on Monday 12:00 ⏱️ #EAU25 🇪🇸 #CytoreductiveSurgery #SABR #Ablation @Connor_Urol @LondonProstate1 @wellcometrust
0
7
13
Next is @Archana_GK1 discussing the #IP9ATLAS trial For active surveillance, is regular MRI superior to standard care for detecting progression? Recruitment is open and the trial will randomise 1263 patients in 30 centres. Watch this space! #EAU25 🇪🇸
0
6
14